Abstract Periconceptional folic acid has been associated with a reduced risk of neural tube defects, but findings on its effect in oral clefts are largely inconclusive. This casecontrol study assesses the effects of periconceptional folic acid on cleft risk, using complementary data from the Dutch Oral Cleft Registry and a population-based birth defects registry (Eurocat) of children and foetuses born in the Northern Netherlands between 1997 and 2009. Cases were live-born infants with non-syndromic clefts (n = 367) and controls were infants or foetuses with chromosomal/syndromal (n = 924) or non-folate related anomalies (n = 2,021). We analyzed type/timing/duration of supplement use related to traditional cleft categories as well as to their timing (early/late embryonic periods) and underlying embryological processes (fusion/differentiation defects). Consistent supplement use during the aetiologically relevant period (weeks 0-12 postconception) was associated with an increased risk of clefts (adjusted odds ratio 1.72, 95 % confidence interval 1.19-2.49), especially of cleft lip/alveolus (3.16, 1.69-5.91). Further analysis systematically showed twofold to threefold increased risks for late differentiation defects-mainly clefts of the lip/ alveolus-with no significant associations for early/late fusion defects. Effects were attributable to folic acid and not to other multivitamin components, and inclusion of partial use (not covering the complete aetiologically relevant period) generally weakened associations. In conclusion, this study presents several lines of evidence indicating that periconceptional folic acid in the Northern Netherlands is associated with an increased risk of clefts, in particular of cleft lip/alveolus. This association is strengthened by the specificity, consistency, systematic pattern, and duration of exposure-response relationship of our findings, underlining the need to evaluate public health strategies regarding folic acid and to further investigate potential adverse effects.
Introduction
There is general consensus that periconceptional folic acid supplementation reduces the risk of neural tube defects. However, although the role of folic acid in oral clefts has been investigated for over 20 years, evidence for a preventive effect in clefts is still lacking and its role remains unresolved [1] [2] [3] .
Oral clefts-one of the most common congenital anomalies in humans-are complex and heterogeneous defects, ranging from mild types to complete clefts affecting the lip, alveolus, and palate. While they can occur as part of a broad range of Mendelian, chromosomal, or teratogenic syndromes [4, 5] , they most commonly occur in isolation. Despite extensive research, the aetiopathogenesis of these non-syndromic (isolated) forms remains largely unknown. They are thought to result from a complex interplay of genetic and environmental factors [4] [5] [6] [7] . Development of the lip, alveolus, and palate entails a complex series of embryological processes, which are related to different time frames in embryogenesis and regulated by many different genes and cell-biological mechanisms [4, [6] [7] [8] . Disruption of any of these tightly regulated processes may result in various cleft sub-phenotypes [4, [6] [7] [8] [9] [10] . Therefore, accurate and detailed phenotyping and subsequent subdivision according to timing and underlying processes is crucial for furthering our understanding of cleft aetiology.
Folate deficiency has been causally related to several congenital anomalies, especially neural tube defects. The neural tube and craniofacial region have quite similar developmental mechanisms [1, 3] , leading to the hypothesis that folate deficiency might also contribute to non-syndromic clefts. Although multiple (non-randomised) observational studies have suggested a beneficial role of folic acid supplements in decreasing cleft risk, the evidence remains largely inconclusive, as many studies-including randomised and cohort controlled trials-identified no significant effects on clefts [1] [2] [3] [11] [12] [13] . Results are often mixed in terms of estimated effects, whether they affect certain or all cleft categories, and whether they are attributable to folic-acid containing multivitamins or folic acid alone. This is partly caused by differences in study populations and designs (including adjustment for confounders) [1, 2] . Additionally, the composition of supplements as well as timing and duration of use varies greatly between studies. Often, supplementation is not subdivided by type (folic acid alone or combined with multivitamins) and does not completely cover the embryonic period of clefts (4-12 weeks postconception) [2, 6, 8] . Another explanation for insufficient evidence might be that heterogeneous cleft groups are generally treated as a single entity to reach adequate statistical power. However, this crude approach may weaken the power to detect effects, given the etiologic and genetic heterogeneity underlying non-syndromic clefts [4, 7] .
We conducted a case-control study to assess the effects of periconceptional folic acid supplements on the risk of oral clefts relative to other non-folate related congenital anomalies. By combining unique complementary data from the Dutch Oral Cleft Registry (NVSCA) and a populationbased birth defects registry (Eurocat Northern Netherlands), we were able to analyse type, timing, and duration of supplement use in relation to timing and embryological mechanisms underlying cleft development.
Methods

Study design and population
We used NVSCA and Eurocat data on children/foetuses born in the Northern Netherlands between 1997 and 2009 inclusive.
The NVSCA is a national register maintained by the Dutch Association for Cleft Palate and Craniofacial Anomalies. Since 1997, the 15 multidisciplinary cleft palate teams in the Netherlands have reported their anonymous live-born patients with clefts (no age limit), prior to cleft surgery. The teams treat virtually all surviving children with clefts who reside in the Netherlands, with a yearly average of 331 new patients, including 40 patients from the Northern Netherlands [14] . To optimise data quality, data are verified on a case-by-case basis, and the teams perform case-ascertainment activities. Additionally, the NVSCA database has been systematically validated [9] .
The population-based Eurocat registry has registered congenital anomalies in the Northern Netherlands since 1981 and now monitors about 18,500 births annually. While it has registry-specific methods for case ascertainment [15] , coding and classification are in concordance with EUROCAT Central Registry guidelines [16] . Children (up to 10 years of age at notification) and foetuses with congenital anomalies are reported by midwifes, well-baby clinic doctors, and specialists. In addition, various sources-mainly hospital registries-are actively searched to find children or pregnancies eligible for registration, including spontaneous abortions and pregnancies terminated for congenital anomalies. Written parental informed consent is needed for registration, and the participation rate is approximately 80 %.
Data collection
Live-born infants with clefts in the Northern Netherlands are reported to the NVSCA by a plastic surgeon during the first patient visit to the team. Using a unique recording system based on the embryology of the head and neck area [8] [9] [10] , the individual cleft anomalies are described in detail by recording the affected anatomical structure (lip/ alveolus/hard palate/soft palate/uvula), the morphology (complete/incomplete/submucous), and the side (left/right/ median). Additionally, infant and parental characteristics and diagnoses of associated congenital anomalies are recorded.
In Eurocat, congenital anomalies-including clefts-are coded according to the ''International Classification of Diseases'' (ninth/tenth revision) [16] . Once an infant has been reported, further information is gathered from the mother. Parents are asked to complete a written questionnaire on medical and reproductive history, occupation, demographic characteristics, maternal weight and height, smoking habits, alcohol consumption, and use of medications and supplements (with specific questions about folic acid and multivitamins) from 3 months before pregnancy through to delivery. In addition, data on any prescribed medication is retrieved from the pharmacy after written parental consent. Subsequently, specific information on whether medications have been actually taken, including the period of use, is verified with the mother in a telephone interview.
Definition of cases and controls
We defined cases as live-born infants with non-syndromic clefts, in other words, those not associated with other major non-folate related congenital anomalies. Median cleft lip/ alveolus and atypical facial clefts were not considered to be oral clefts because of their different pathogenesis [17] . For inclusion, cases had to be registered in both databases, which allowed us to combine detailed information on cleft phenotype (NVSCA) with complementary data on maternal characteristics and folic acid supplement use (Eurocat). Data linkage was performed using key (e.g., date of birth and gender) and cleft information. Discrepancies between registries regarding this information were verified with the cleft palate teams and, if applicable, corrected in the study database. Non-matching cases from either registry were similarly verified, and if sufficient matching information was found they were added to the database. Using these steps, 91.6 % (463/505) of the Eurocat and 76.0 % (443/ 583) of the NVSCA cases were matched. The reasons why cases could not be matched are displayed in the figure of online resource 1. As shown here, the main reason that NVSCA cases had not been registered in Eurocat was the lack of permission from parents for registration in Eurocat (n = 34). Note that these cases showed a cleft distribution generally similar to that of the matched cases. Conversely, Eurocat cases were not registered in the NVSCA mainly due to postnatal death (n = 31). However, except for 2 cases, all died because of syndromal or chromosomal anomalies, and therefore these infants would have been excluded from the study anyway. As presented in the figure, a total of 474 cases were finally matched, and after exclusion of the syndromic (associated) matched cases (n = 48), a total of 426 potential cases remained in the study.
Eurocat does not register non-malformed children, and controls were therefore defined as infants or foetuses with chromosomal/syndromal defects or non-folate related congenital anomalies. The rationale for choosing chromosomal and syndromal defects is that the origin of these disorders is not related to folic acid. The use of malformed controls from birth years and geographical areas similar to those of the cases is widely accepted and beneficial with regard to internal validity, as it minimises the potential for differential recall bias and other possible sources of differential exposure ascertainment compared to controls without congenital anomalies [18] [19] [20] [21] [22] . We excluded infants with anomalies previously associated with folic acid or having developmental mechanisms similar to clefts (neural tube defects, n = 213; congenital heart defects, n = 1,692; hypospadias, n = 472; body wall defects, n = 91; limb reduction defects, n = 157; iris colobomas, n = 16; and diaphragmatic hernias, n = 43) [1, 3, [22] [23] [24] , resulting in a total of 3,754 potential controls.
Oral cleft classification
To be consistent with literature [4, 7, 10, [25] [26] [27] , we first divided cases into three categories: cleft lip/alveolus only, cleft lip/alveolus and palate, and cleft palate only. Besides this generally accepted broad division, cases were also classified according to timing and underlying developmental mechanisms.
In short, embryogenesis of the primary palate (presumptive lip and alveolus) and secondary palate (presumptive hard and soft palates, including uvula) can be subdivided into an early (4-7 weeks postconception) and late (7-12 weeks postconception) developmental period. During the early embryonic period, the primary palate is formed by outgrowth and fusion of the facial swellings.
Subsequently-during the late period-the definitive lip and alveolus are formed by outgrowth and differentiation of mesenchyme into bone and musculature. By contrast, the secondary palate develops only during the latter period by outgrowth and fusion of the palatine processes and subsequent differentiation of its mesenchyme into bone and musculature [6, 8, 9] .
Derailments in fusion and/or differentiation processes may result in various cleft sub-phenotypes. For example, interrupted fusion of the primary palate may cause a complete cleft lip/alveolus, while defective fusion of the secondary palate may give rise to a complete or incomplete cleft palate. Additionally, disruptions in differentiation of the primary or secondary palates may result in an incomplete or submucous cleft lip/alveolus or submucous cleft palate, respectively. Note that more than one of these processes can be disturbed during development, resulting in different combinations of defects [6, 8, 9] .
Based on the early and late embryogenesis described above, cases were first classified into early and late defects and then into fusion and/or differentiation defects. Details of this classification have been described elsewhere [8, 9] .
Periconceptional folic acid supplements
To prevent neural tube defects, Dutch women planning a pregnancy are recommended to take 400 lg folic acid/day from 4 weeks before until 8 weeks after conception [28, 29] . However, this period covers only the early, but not the late, embryonic period for clefts. Therefore, we evaluated supplement use during the recommended period, as well as during the early and late embryonic periods mentioned above [6, 8, 9] , i.e., the aetiologically relevant time periods for clefts. As for neural tube defects, we included 4 weeks prior to these embryonic periods to reach adequate folate status for prevention, resulting in the following aetiologically relevant periods: all clefts (0-12 weeks postconception), early defects (0-7 weeks postconception), and late defects (3-12 weeks postconception).
Infants were initially excluded from the study if the mothers' use of folic acid supplements was unknown or the period of use was unknown (50 cases, 724 controls). They were also excluded if the mother had used folic acid antagonists, which interfere with folate metabolism [18] [19] [20] , including dihydrofolate reductase inhibitors (methotrexate, sulfasalazine, triamterene, pyrimethamine, and trimethoprim) or antiepileptic drugs (5 cases, 47 controls). Additionally, infants with reported maternal diabetes mellitus prior to or during pregnancy were excluded (4 cases, 38 controls), because clefts have been associated with maternal diabetes [30] .
Statistical analysis
The following potential confounders were explored using the Chi squared test: year of baby's birth, number of babies/foetuses delivered, number of previous live births, fertility problems, maternal age and BMI, mother's education level, and smoking and alcohol use. To estimate cleft risks, we calculated crude and adjusted odds ratios using univariate and multivariate logistic regression models, respectively. First, we evaluated the use of any supplement, and if possible, we subsequently stratified the analyses into folic acid alone and multivitamins (containing folic acid). Two-tailed values of p \ 0.05 and 95 % confidence intervals (CI) excluding 1.0 were considered statistically significant. Analyses were performed using SPSS software version 19.0.
Results
In total, 367 cases and 2,945 controls (924 infants with chromosomal defects and 2,021 with non-folate related anomalies) were included. Apart from the higher proportions of boys and previous live births among cases, no further significant differences in infant or maternal characteristics were found between cases and controls (Table 1) .
Generally, mothers who had used supplements had either taken folic acid alone or multivitamins (containing folic acid), at a daily dose of 400 lg. As presented in Table 2 , case mothers reported any periconceptional folic acid supplement use more frequently than control mothers. More specifically, consistent use of any supplement during the entire recommended period or aetiologically relevant cleft periods was more frequently reported among cases, while partial use was more frequently reported among controls. Stratum analysis revealed similar figures for use of folic acid alone (not as a multivitamin). As shown in Table 3 , consistent use of any supplement or folic acid alone during the entire aetiologically relevant cleft period (0-12 weeks postconception) was associated with a significantly increased risk of all clefts, and in particular of cleft lip/alveolus only. Adjustment for potential confounders resulted in about one-and-a-half time higher risks for all clefts and threefold increased risks for cleft lip/ alveolus. After inclusion of partial use during the aetiologically relevant period, the size, but not the direction, of the effects were reduced (except for multivitamins, Table 3 ). Overall, associations were also somewhat weakened by restricting analysis of use to the recommended period until 8 weeks, instead of the aetiologically relevant period until 12 weeks postconception (see online resource 2). Exploration of a possible genetic background revealed that a positive family history for clefts was less frequently reported for cases with cleft lip/alveolus (2.5 %, 3/120) than cases with other cleft categories (11.4 %, 28/245; p = 0.004, data not further shown).
To gain more insight into the detected effects, clefts were also classified according to timing and underlying processes in embryogenesis. Table 4 shows that clefts of the lip/alveolus mainly consisted of late differentiation defects (70.2 %, 85/121). The estimated risks for early and late defects-including fusion and/or differentiation defects-are shown in Table 5 . Consistent supplement use during 0-7 weeks postconception was not significantly associated with higher risks of early defects (mainly fusion defects). Similarly, consistent use during 3-12 weeks postconception did not significantly increase the risk of late defects. Further subgroup analysis also showed no significant crude associations. However, after adjustment for potential confounders, we found twofold to threefold increased risks just for late differentiation defects, regardless of supplement type. Similar to the cleft category analysis, inclusion of partial use during the aetiologically relevant periods reduced the size, but not the direction, of associations (see online resource 2).
Finally, if analyses were restricted to only chromosomal defects (n = 924) or only live births (n = 2,895) as controls, no significant changes in our risk estimates were detected (data not further shown).
Discussion
This population-based case-control study provides the first evidence that periconceptional folic acid supplementation might be associated with elevated risks for certain types of oral clefts. Defects of the lip/alveolus-mainly resulting from defective differentiation in development-appeared to account for the largest proportion of the risk increase, being associated with more than threefold higher risks after Given that stratum analysis revealed similar figures for folic acid alone, effects were attributable to folic acid and not to other multivitamin components. Furthermore, a duration of exposure-response relationship was shown, as 
Strengths and weaknesses
By combining complementary NVSCA and Eurocat data, we were able to investigate type, timing, and duration of periconceptional folic acid supplement use in relation to traditional cleft categories as well as to their timing and underlying embryological processes-an approach not used in earlier studies [1, 2] . The rationale of this approach was based on the early and late embryogenesis, in line with the theoretical basis of the NVSCA system [6, [8] [9] [10] . The unique data combination, allowing us to use a relatively large sample drawn from a well-defined and homogenous population, gave our study its main strength. However, there were also some limitations, mostly inherent to the observational nature of our study. As information on folic acid supplement use and potential confounders was mainly obtained from retrospective questionnaires, recall bias might be a concern. However, although misclassification and measurement errors inevitably occur, the use of malformed controls minimised differential recall between cases and controls. This is reflected in the equal distribution of other exposures among cases and controls for which socially desirable answers could be expected, like maternal smoking and alcohol use. Concerns about recall bias were further reduced by the specificity, consistency, and systematic character of the observed effects, including the duration of exposure-response relationship.
Another limitation is that we were not able to investigate dose effects because a fixed dose of 400 lg is recommended for the periconceptional period in the Netherlands, and high dose (5 mg) supplements are only prescribed for certain medical indications (e.g., previous pregnancy affected with a neural tube defect). Additionally, exact intake could not be measured because we had to rely on information about supplement use from retrospective questionnaires, and data on folate concentrations in serum and red blood cells were not available. While verification of the products that had been used by cases and controls showed dosages similar to the recommended periconceptional dose (400 lg), dietary intake was not known, which limited our knowledge on folate status. In addition, since parents have to give informed consent for registration in Eurocat, there is a possibility of selection bias due to this informed consent. However, we assume that not giving the consent is equally distributed among cases and controls, given that both had congenital anomalies. Furthermore, the cases with parental refusal showed a cleft distribution generally similar to that of the included cases, which suggests that refusal occurred not just in selective groups. Conversely, the NVSCA registers only patients who survive long enough to reach a cleft palate team. Theoretically, this might also affect results, but in our study, almost all postnatal deaths had syndromal or chromosomal anomalies and would therefore have been excluded anyway. Another source of selection bias might be the inclusion of pregnancy terminations and stillbirths among controls in our study. However, we believe this to be minimal, because restricting analyses to live births only did not significantly alter our risk estimates.
Another weakness might be the presence of unidentified confounding factors. Even though we used malformed controls and were well informed about maternal health and lifestyle factors as well as use of medications (folic acid antagonists), there may still have been confounding by other closely related factors. However, such confounders would have to be strongly related to specific cleft defects and folic acid use to produce the observed results.
Although the use of malformed controls is beneficial with regard to internal validity, it might also have its restrictions, as it could lead to risk over-or underestimations if anomalies in the control group were also associated with folic acid. However, we assume this to be minimal because suspected folate-related anomalies were excluded by design, and further restrictions to purely chromosomal anomalies (i.e., excluding the largest subgroup having nonchromosomal anomalies) did not substantially change our risk estimates. Additionally, Van Beynum et al. [22] recently used similar methods and comparable controls drawn from the same Eurocat population to demonstrate significant reduced risks for congenital heart defects associated with periconceptional folic acid use in the Northern Netherlands. As stated by these authors, their findings are in line with earlier findings of a Hungarian randomized controlled trial [12] and other observational studies [22] , thereby supporting the validity of malformed controls. Moreover, they demonstrated that such controls are representative for the general population, as they found overall similar risk estimates using reference groups from the general population. Because we investigated supplement use in great detail and considered many potential confounders, these reference groups-for which just minimal information on absence or presence of folic acid use was available-could not be used in our study.
Possible explanations
The specificity and systematic pattern in our findings is consistent with recent embryological and epidemiological data, suggesting that clefts of the lip/alveolus have unique genetic and etiologic features [4, 6, 7, 10, [25] [26] [27] . However, our results are in contrast with previous studies on the effects of periconceptional folic acid in clefts, which showed either preventive or no effects [1] [2] [3] 31] . More specifically, one of the first positive effects were reported by Tolarova, who found an 84 % reduction in recurrence of cleft lip/alveolus with or without cleft palate after supplementation of multivitamins and high dose (10 mg) folic acid during 3 months before and after pregnancy [32] . However, this study was limited by the small number of cases as well as by its non-randomized nature. In contrast, the only two intervention trials that considered oral clefts and were reported-comprising a randomized controlled trial and cohort-controlled trial from Hungary in 1992 and 2004, respectively-showed no reduction or increase in the prevalence of cleft lip/aveolus with or without palate or cleft palate alone after supplementation of multivitamins with 800 lg folic acid [11, 13] . This might partly be explained by the low statistical power due to limited number of subjects. Among observational studies, the Hungarian case-control study of Czeizel et al. [33] indicated a dose-dependent preventive effect of folic acid on the risk of clefts. Additionally, Li et al. [34] recently performed a Chinese prospective cohort study, showing a reduced risk for cleft lip with or without palate among women who had used periconceptional folic acid in a northern rural region of China with a proven high prevalence of folate deficiency. However, this reduced risk was mainly attributable to cleft lip and palate and not to cleft lip only, the category for which our study showed the most elevated risk. Furthermore, no significant effects were found in a more southern region with an overall higher socioeconomic status and generally greater availability of fresh vegetables, resulting in a better folate status. An important limitation of this study was that folic acid use was not randomised, and that women who had taken folic acid may thus have differed systematically in other factors that could have influenced the prevalence of clefts. As the authors did not have information on risk factors found in our and other studies to be important, such as smoking and alcohol [1] , they were not able to adjust for these factors.
The mechanisms by which folic acid might prevent certain congenital anomalies remains unexplained, but we do know that other aspects surrounding folate metabolism have also been shown to deviate for clefts. For example, in some studies, the association with the CT/TT genotype of the MTHFR gene appeared to be a protective factor instead of a risk factor for clefts [35] [36] [37] [38] , or it appeared to be an even greater risk factor if the mother had used folic acid supplements [38] . Moreover, inhibiting folic acid binding to folate receptor has been shown to reduce the cleft risk [39] . Finally, some studies have found that increased plasma or erythrocyte folate (a parameter for long-term folate status) is associated with elevated, rather than decreased, cleft risks [35, 40, 41] .
Given that the Northern Netherlands has a rather homogenous population with relatively high cleft rates [14] , a higher genetic predisposition might have contributed to our findings. This could specifically have affected differentiation defects, as differentiation and fusion processes are regulated by different genes and cell-biological processes [4, 6] . However, this explanation was not supported by our exploratory analysis of relatives with oral clefts, which showed relatively low proportions of cleft relatives among cases with these specific defects.
To our knowledge, our study is the first to report a negative effect of folic acid supplementation on the risk of an isolated congenital anomaly. However, previous reports have shown comparable associations between periconceptional folic acid supplements/multivitamins/cereals and the occurrence of multiple congenital anomalies [42, 43] . Furthermore, several animal studies have also demonstrated adverse effects linking high folate intake to embryonic delay, growth retardation, congenital heart defects [44] [45] [46] . In humans, folate intake and blood cell concentrations increased significantly due to folate fortification and additional supplementation [47, 48] , but the consequences of long-term high folate intake are not known yet. Recently, it has been hypothesized that folic acid intake might lead to changes in epigenetic patterns, thereby altering gene expression [49] [50] [51] . This might help to explain different health outcomes (e.g., congenital anomalies) among those with similar genetic backgrounds.
Possible implications
Our findings may have implications for healthcare and policy makers. First, oral clefts require extensive multidisciplinary treatment and account for substantial morbidity among infants. Therefore, higher cleft risks will increase the public health burden in terms of medical costs and emotional stress to patients and their families [4, 5, 7] . Second, if our findings are correct, it is vital to restrict the use of folic acid to the official recommended period of 4 weeks before to 8 weeks after conception, that is the aetiologically relevant period for neural tube defects [29] . Minimising pregnant women's exposure to folic acid in this way may then reduce cleft prevalence. More generally, our study underlines the importance of evaluating public health strategies regarding folic acid supplementation, including its timing, duration, and dose, which should be done in the light of potential dietary improvements. Together with other emerging studies on the potential adverse effects of increased folic acid intake [44] [45] [46] [49] [50] [51] , our findings also underscore the need for additional studies on the consequences of increased folic acid intake. Large population-based studies using other datasets, but the same approach and methodology as in the current study, are needed to confirm or refute our findings. To gain more insight into the role of folic acid in the aetiology of clefts and other congenital anomalies, future studies should evaluate effects according to timing and embryological mechanisms underlying their development.
Conclusions
This study presents several lines of evidence indicating that periconceptional folic acid in the Northern Netherlands is associated with an increased risk of clefts, especially of the lip/alveolus, relative to non-folate related malformations. Although detected by an observational study, this association is strengthened by the specificity, consistency, systematic pattern, and duration of exposure-response relationship of our findings. Ideally, a randomized controlled trial should be conducted to confirm or refute our findings, but this would be unethical with the knowledge that folic acid can prevent neural tube defects. Therefore, it is advisable to restrict folic acid supplementation to the period recommended for neural tube defects until more information is available.
